The global pharmaceutical contract manufacturing market has witnessed a significant growth over the past five years and is likely to grow moderately over the next few years. The increasing presence of generic drugs in the market, shrinking average patent life, and high pressure from governments to reduce the retail price of drugs are some of the factors driving the market.On an average, the entire drug development cycle takes anywhere between 8 and 15 years and the associated costs (i.e. from new molecule discovery to market the

final product) is approximately $800 million. Moreover, post regulatory approval,drugmakers need to maintain the huge supply in order to cater to the existing demand. To maintain the timeline as well as adequate supply with the set quality standards, drugmakers opt for contract manufacturing.In this report, Technavio covers the present scenario and growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020 (base year: 2015;forecast end year: 2020).

PART 01: Executive summary 6

Highlights 6

PART 02: Scope of the report 7

Market overview 7

Top-vendor offerings 7

PART 03: Market research methodology 9

Research methodology 9

Economic indicators 9

PART 04: Introduction 10

Key market highlights 10

PART 05: Pharmaceutical manufacturing outsourcing 13

Increased regulatory guidelines coupled with healthcare

cost containment efforts 17

Rapid innovation and reduced product development

lifecycle 17

High capital investment 17

PART 06: Market landscape 19

Market overview 19

Five forces analysis 28

PART 07: Market segmentation by type of contract

manufacturing 29

Global API/bulk drug contract manufacturing market 30

Global FDF market 35

PART 08: Geographical segmentation 38

Global pharmaceutical contract manufacturing market by

geography 38

Pharmaceutical contract manufacturing market in

Americas 40

Pharmaceutical contract manufacturing market in

APAC 41

Pharmaceutical contract manufacturing market in

EMEA 41

PART 09: Key leading countries 43

PART 10: Market drivers 44

Increased focus on core competence 44

High number of US FDA-approved manufacturing

facilities in emerging countries 46

Shorter time-to-market 47

PART 11: Impact of drivers 48

PART 12: Market challenges 49

Capacity utilization issues and lack of information

integration 49

Growing global competition 50

Lack of manufacturing standardization 51

PART 13: Impact of drivers and challenges 52

PART 14: Market trends 53

Consolidation through vertical integration, alliances, and

acquisitions 53

Huge demand for next-generation biologics 55

Value-added services 57

PART 15: Vendor landscape 58

Competitive scenario 58

PART 16: Key vendor analysis 62

Catalent 62

Lonza 66

Pfizer CentreOne 69

Other prominent vendors 73

PART 17: Appendix 79

List of abbreviations 79

PART 18: Explore Technavio 80